Indication for Liver Transplantation After Direct-Acting Agents in the Treatment of Patients With Hepatitis C

• Published in: Transplantation proceedings Vol. 54; no. 1; pp. 32 - 34
• Main Authors: Arias, Ana Belén Vico, Villegas Herrera, María Trinidad, Arco Sánchez, Alba, Adel, Moisés El, Triguero Cabrera, Jennifer, Plata Illescas, Cristina, Montes Osuna, Maria Carmen, Santoyo Villalba, Julio, Villar del Moral, Jesús María
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2022
• Subjects: Antiviral Agents - therapeutic use; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - surgery; Hepacivirus; Hepatitis C - drug therapy; Hepatitis C, Chronic - drug therapy; Humans; Liver Neoplasms - drug therapy; Liver Neoplasms - surgery; Liver Transplantation; Retrospective Studies
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2021.08.058

The development of new direct-acting antivirals (DAA) for hepatitis C virus (HCV) treatment has reduced the indications for liver transplantation (LT). We analyzed the indications, characteristics, and evolution of patients with HCV infection who were treated with DAA-based therapies and who underwent LT. A retrospective single-center study was performed. Data were collected of patients undergoing LT owing to HCV infection between January 2016 and August 2020. Overall characteristics of the patients were analyzed and divided into 2 groups according to the indication for LT: hepatocellular carcinoma (HCC) or decompensated cirrhosis (DC). Differences between biliary and vascular complications after surgery and survival time were compared. Of 156 LTs, 33 (22%) were performed in patients with HCV infection in this period, which shows a decrease of nearly 16% when comparing this period with the interferon/ribavirin era. Indications for LT were 56.7% in patients with HCC and 43.3% in patients with DC. After DAA treatment, all patients developed a sustained viral response. Mean age of the global series, HCC group, and DC group were 56.9, 58.71, and 54.4 years, respectively (P = .041); 53.8% of the HCV-DC group initiated DAA treatment by the time to be included at the waiting list, compared with 17.6% of HCV-HCC group (P = .045). There were no statistically significant differences in terms of survival or biliary and vascular complications after LT. Patients with HCV are still part of the waiting list, mainly because of HCC. No statistical differences were shown in terms of postoperative complications or survival. Studies with a higher number of patients are needed.